Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome

ABSTRACT: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by pregnancy morbidity or thrombosis and persistent antiphospholipid antibodies (aPL) that bind to the endothelium and induce endothelial activation, which is evidenced by the expression of adhesion molecules and the production of reactive oxygen species (ROS) and subsequent endothelial dysfunction marked by a decrease in the synthesis and release of nitric oxide (NO). These endothelial alterations are the key components for the development of severe pathological processes in APS. Patients with APS can be grouped according to the presence of other autoimmune diseases (secondary APS), thrombosis alone (thrombotic APS), pregnancy morbidity (obstetric APS), and refractoriness to conventional treatment regimens (refractory APS). Typically, patients with severe and refractory obstetric APS exhibit thrombosis and are classified as those having primary or secondary APS. The elucidation of the mechanisms underlying these alterations according to the different groups of patients with APS could help establish new therapies, particularly necessary for severe and refractory cases. Therefore, this study aimed to evaluate the differences in endothelial activation and dysfunction induced by aPL between patients with refractory obstetric APS and other APS clinical manifestations. Human umbilical vein endothelial cells (HUVECs) were stimulated with polyclonal immunoglobulin-G (IgG) from different groups of patients n = 21), including those with primary (VTI) and secondary thrombotic APS (VTII) and refractory primary (RI+), refractory secondary (RII+), and non-refractory primary (NR+) obstetric APS. All of them with thrombosis. The expression of adhesion molecules; the production of ROS, NO, vascular endothelial growth factor (VEGF), and endothelin-1; and the generation of microparticles were used to evaluate endothelial activation and dysfunction. VTI IgG induced the expression of adhesion molecules and the generation of microparticles and VEGF. RI+ IgG induced the expression of adhesion molecules and decreased NO production. RII+ IgG increased the production of microparticles, ROS, and endothelin-1 and reduced NO release. NR+ IgG increased the production of microparticles and endothelin-1 and decreased the production of VEGF and NO. These findings reveal differences in endothelial activation and dysfunction among groups of patients with APS, which should be considered in future studies to evaluate new therapies, especially in refractory cases.

• Autores: Cadavid Jaramillo, Angela Patricia; Velásquez Berrío, Manuela; Peláez Tabares, Luisa Fernanda; Rojas López, Mauricio; Narváez-Sánchez, Raúl; Velásquez Penagos, Jesús Arnulfo; Escudero, Carlos Alonso; San Martín Henríquez, Sebastián
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2021
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/43623
• Acceso en línea: https://hdl.handle.net/10495/43623; http://www.frontiersin.org/physiology/archive
• Palabra clave: Células Endoteliales; Endothelial Cells; Inmunoglobulina G; Immunoglobulin G; beta 2 Glicoproteína I; beta 2-Glycoprotein I; Síndrome Antifosfolípido; Antiphospholipid Syndrome; Enfermedades Vasculares; Vascular Diseases; Endotelio; Endothelium; endothelial activation and dysfunction; https://id.nlm.nih.gov/mesh/D042783; https://id.nlm.nih.gov/mesh/D007074; https://id.nlm.nih.gov/mesh/D053482; https://id.nlm.nih.gov/mesh/D016736; https://id.nlm.nih.gov/mesh/D014652
• Rights: openAccess
• License: http://creativecommons.org/licenses/by/2.5/co/